BioNTech SE (BNTX): What the Financials Tell Us

BioNTech SE (NASDAQ:BNTX) saw an upside of 2.31% to $249.40 after adding $5.63 on Wednesday. The 5-day average trading volume is 1,538,923 shares of the company’s common stock. It has gained $257.90 in the past week. An average of 3,053,406 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 4,356,829.

BNTX’s 1-month performance is -25.48% or -$78.54 on its low of $230.03 reached on 10/01/21. The company’s shares have touched a 52-week low of $75.35 and high of $464.00, with the stock’s rally to the 52-week high happening on 08/10/21. YTD, BNTX has achieved 199.03% or $167.08. However, the current price is down -46.25%% from the 52-week high price.

A Backdoor Way To Profit From Today’s Crypto Bull Market

In any crypto bull market, there's a lot of money to be made.

But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?

This strategy is simply and ridiculously easy.

Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.


Valuation Metrics

The company’s PE ratio for the last five years has touched a high of 749.25 and a low of 10.77. BNTX stock has a beta of 0.00. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 6.60 while the price-to-book (PB) in the most recent quarter is 9.39.

BioNTech SE’s quick ratio for the period ended June 29 was 2.60, with the current ratio over the same period at 2.70 meaning that BNTX stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.09, while the total debt to equity was 0.22. In terms of profitability, the gross margin trailing 12 months is 85.00%. The trailing 12-month EBITDA margin is -47.24% while for the period ending June 29; BioNTech SE’s operating margin was 76.20%. The firm’s gross profit as reported stood at $483.18 million against revenue of $550.96 million.

Earnings Surprise

For the quarterly period ending June 29 this year, BioNTech SE’s cash and short-term investments amounted to $1.01 million against total debt of $256.8 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 77.49% to $540.2 million, while revenue of $0.0 was 100.0% off the previous quarter. Analysts expected BNTX to announce $8.77 per share in earnings in its latest quarter, but it posted $12.46, representing a 42.10% surprise. EBITDA for the quarter stood at more than $5.08 billion. BNTX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 4.42 billion, with total debt at $256.8 million

Technical Picture

Let’s look briefly at BioNTech SE (BNTX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 32.16% to suggest the stock is trending Neutral, with historical volatility in this time period at 52.43%.

The stock’s 5-day moving average is $245.58, reflecting a +5.27% or $12.46 change from its current price. BNTX is currently trading -30.02% above its 20-day SMA, +27.04% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -29.34% and +182.14% respectively.

Stochastic %K and %D was 11.97% and 11.52% and the average true range (ATR) pointed at 16.97. The RSI (14) points at 34.69%, while the 14-day stochastic is at 15.36% with the period’s ATR at 19.02. The stock’s 9-day MACD Oscillator is pointing at -1.30 and -18.11 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for BioNTech SE (NASDAQ: BNTX), Jefferies launched coverage with a Hold rating. Analysts offering their rating for BNTX stock have a consensus rating for the stock as Hold. Currently, 1 brokerage advisors rate BNTX as a “sell,”, while 8 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 0 rates the stock as overweight while 4 have offered a “buy” rating.

What is BNTX’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $130.36 and a high of $384.66, with their median price target at $311.97. Looking at these predictions, the average price target given by analysts is for BioNTech SE (BNTX) stock is $287.09.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam